Pharmaceutical Technology18d
Dupilumab by Regeneron Pharmaceuticals for Bullous Pemphigoid: Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase III drugs for Bullous Pemphigoid does not have ...
Pharmaceutical Technology18d
Dupilumab by Regeneron Pharmaceuticals for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...
clinicaltrialsarena21d
Sanofi to increase competition in atopic dermatitis market after Dupixent success
Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone for ...
National Institute for Health and Care Excellence1mon
Published guidance, NICE advice and quality standards
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy TA117 24 January 2007 24 January 2007 Methadone and buprenorphine ...
National Institute for Health and Care Excellence1y
Published guidance, NICE advice and quality standards
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...